ジドロゲステロン市場：タイプ別、用途別-2024～2030年の世界予測

ジドロゲステロン市場規模は2023年に5億6,786万米ドルと推定され、2024年には6億1,812万米ドルに達すると予測され、CAGR 9.45%で2030年には10億6,900万米ドルに達すると予測されます。

ジドロゲステロンの世界市場

ジドロゲステロンは、内因性プロゲステロンと化学構造と薬理作用が類似した合成ホルモンです。プロゲスチンに分類され、天然ホルモンであるプロゲステロンの効果を再現するために使用される医薬品の一種です。ジドロゲステロンは強い黄体ホルモン作用を持つため、プロゲステロン欠乏症に非常に適しています。月経障害、黄体機能不全による不妊症、更年期障害のホルモン補充療法（HRT）など、さまざまな臨床場面で頻繁に使用されています。他の合成黄体ホルモン剤とは異なり、ジドロゲステロンは治療用量において排卵を阻害しないため、排卵周期の維持が望まれる場合に好ましい選択肢となります。ジドロゲステロン市場は、高齢女性人口の増加やリプロダクティブ・ヘルス問題の蔓延、医療インフラの改善、医療の進歩、女性の健康に対する政府の支援政策などにより成長を示しています。成長の展望とは裏腹に、厳しい医薬品承認規制、副作用、市場競争などの課題が市場の拡大を妨げています。しかし、新たなドラッグデリバリー機構の開拓、費用対効果を高めるためのジェネリック医薬品の導入、幅広い治療用途に向けた併用療法の研究などは、将来の市場成長にとって有利な機会をもたらします。

地域別洞察

南北アメリカのジドロゲステロン市場は安定した成長パターンを経験しています。女性の健康問題に対する意識の高まりと、女性人口における子宮内膜症や月経不順などの疾患の流行が、ホルモン関連の治療オプションに対する需要を後押ししています。米国は、確立された医療インフラ、大手製薬会社の存在、支持的な規制の枠組みにより、この地域の市場成長に大きく貢献しています。これに加えて、このような医薬品に対する高い購買力と保険適用が、ジドロゲステロン市場の好調な軌道を後押ししています。欧州は、ホルモン補充療法が広く受け入れられ、有利な医療償還政策により、欧州、中東、アフリカのジドロゲステロン市場に大きく貢献しています。同地域の成熟した医療システムは、同地域の強力な市場ポジションに貢献しています。一方、中東・アフリカ地域は、医療投資の増加や女性のリプロダクティブ・ヘルスに関する意識の緩やかな普及により、欧州に比べ成長率は鈍化しているもの、成長の可能性を示しています。アジア太平洋のジドロゲステロン市場は、最も高い成長率が見込まれています。この拡大を後押しする要因としては、婦人科疾患の罹患率の上昇、女性労働人口の増加、医療インフラの改善、女性の健康問題に対する意識の高まりなどが挙げられます。特に、中国やインドを含む国々では医薬品部門が急成長しており、人口の多さと医療ツーリズムの増加により、大きな市場となっています。

FPNVポジショニングマトリックス

FPNVポジショニングマトリックスはジドロゲステロン市場を評価する上で極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます。フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、ジドロゲステロン市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1-市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発とイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1-ジドロゲステロン市場の市場規模と予測は？

2-ジドロゲステロン市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3-ジドロゲステロン市場における技術動向と規制の枠組みは？

4-ジドロゲステロン市場における主要ベンダーの市場シェアは？

5-ジドロゲステロン市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 高齢女性人口の増加とリプロダクティブ・ヘルス問題の蔓延
    • 女性の健康に対する政府の支援政策
    • 経済全体にわたる医療インフラの改善
  • 抑制要因
    • ジドロゲステロンの制作に伴う高額なコスト
  • 機会
    • ジドロゲステロンジェネリック医薬品の承認の増加
    • 市場関係者による投資と拡大の拡大
  • 課題
    • ジドロゲステロン医薬品に関連する厳格な規制承認プロセス
• 市場セグメンテーション分析
  • タイプ：高精度の分析と臨床検査におけるジドロゲステロンd6の利点
  • 用途：婦人科疾患における症状の緩和とホルモン調節に対するジドロゲステロンの重要な用途
• 市場動向分析
• 高インフレの累積的影響
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 規制の枠組み

第6章 ジドロゲステロン市場：タイプ別

• イントロダクション
• D5
• D6

第7章 ジドロゲステロン市場：用途別

• イントロダクション
• 婦人科疾患
• 不妊

第8章 南北アメリカのジドロゲステロン市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋のジドロゲステロン市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカのジドロゲステロン市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• FPNVポジショニングマトリクス
• 市場シェア分析：主要企業別
• 競合シナリオ主要企業別の分析
  • 合併・買収
  • 受賞・表彰・拡大

第12章 競合ポートフォリオ

• 主要な企業プロファイル
  • Abbott Laboratories
  • Adalvo Limited
  • Alembic Pharmaceuticals Limited
  • Axios Research
  • Clearsynth
  • Dr. D Pharma
  • Gufic Group
  • H & Care Incorp
  • Jagsonpal Pharmaceuticals Ltd.
  • Mankind Pharma Limited
  • Medley Pharmaceuticals Ltd.
  • Merck KGaA
  • Sandoo Pharmaceuticals and Chemcials Co.,Ltd.
  • Santa Cruz Biotechnology, Inc.
  • Simson Pharma Limited
  • Solitaire Pharmacia Private Limited
  • Somacare
  • Synokem Pharmaceuticals Ltd.
  • Taj Pharmaceuticals Limited
  • Theramex
  • TLC Pharmaceutical Standards Ltd.
  • Viatris Inc.
  • VIVAN Life Sciences
  • Zuventus Healthcare Limited
• 主要な製品ポートフォリオ

第13章 付録

• ディスカッションガイド
• ライセンスと価格について

LIST OF FIGURES

• FIGURE 1. DYDROGESTERONE MARKET RESEARCH PROCESS
• FIGURE 2. DYDROGESTERONE MARKET SIZE, 2023 VS 2030
• FIGURE 3. DYDROGESTERONE MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. DYDROGESTERONE MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. DYDROGESTERONE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. DYDROGESTERONE MARKET DYNAMICS
• FIGURE 7. DYDROGESTERONE MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 8. DYDROGESTERONE MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. DYDROGESTERONE MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 10. DYDROGESTERONE MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. AMERICAS DYDROGESTERONE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 12. AMERICAS DYDROGESTERONE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. UNITED STATES DYDROGESTERONE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 14. UNITED STATES DYDROGESTERONE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. ASIA-PACIFIC DYDROGESTERONE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 16. ASIA-PACIFIC DYDROGESTERONE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA DYDROGESTERONE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA DYDROGESTERONE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. DYDROGESTERONE MARKET, FPNV POSITIONING MATRIX, 2023
• FIGURE 20. DYDROGESTERONE MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

• TABLE 1. DYDROGESTERONE MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. DYDROGESTERONE MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL DYDROGESTERONE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. DYDROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 6. DYDROGESTERONE MARKET SIZE, BY DYDROGESTERONE D5, BY REGION, 2018-2030 (USD MILLION)
• TABLE 7. DYDROGESTERONE MARKET SIZE, BY DYDROGESTERONE D6, BY REGION, 2018-2030 (USD MILLION)
• TABLE 8. DYDROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 9. DYDROGESTERONE MARKET SIZE, BY GYNECOLOGICAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. DYDROGESTERONE MARKET SIZE, BY INFERTILITY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. AMERICAS DYDROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 12. AMERICAS DYDROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 13. AMERICAS DYDROGESTERONE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 14. ARGENTINA DYDROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 15. ARGENTINA DYDROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 16. BRAZIL DYDROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 17. BRAZIL DYDROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 18. CANADA DYDROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 19. CANADA DYDROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 20. MEXICO DYDROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 21. MEXICO DYDROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 22. UNITED STATES DYDROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 23. UNITED STATES DYDROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 24. UNITED STATES DYDROGESTERONE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 25. ASIA-PACIFIC DYDROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 26. ASIA-PACIFIC DYDROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 27. ASIA-PACIFIC DYDROGESTERONE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 28. AUSTRALIA DYDROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 29. AUSTRALIA DYDROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 30. CHINA DYDROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 31. CHINA DYDROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 32. INDIA DYDROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 33. INDIA DYDROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 34. INDONESIA DYDROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 35. INDONESIA DYDROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 36. JAPAN DYDROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 37. JAPAN DYDROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 38. MALAYSIA DYDROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 39. MALAYSIA DYDROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 40. PHILIPPINES DYDROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 41. PHILIPPINES DYDROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 42. SINGAPORE DYDROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 43. SINGAPORE DYDROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 44. SOUTH KOREA DYDROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 45. SOUTH KOREA DYDROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 46. TAIWAN DYDROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 47. TAIWAN DYDROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 48. THAILAND DYDROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 49. THAILAND DYDROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 50. VIETNAM DYDROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 51. VIETNAM DYDROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 52. EUROPE, MIDDLE EAST & AFRICA DYDROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 53. EUROPE, MIDDLE EAST & AFRICA DYDROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 54. EUROPE, MIDDLE EAST & AFRICA DYDROGESTERONE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 55. DENMARK DYDROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 56. DENMARK DYDROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 57. EGYPT DYDROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 58. EGYPT DYDROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 59. FINLAND DYDROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 60. FINLAND DYDROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 61. FRANCE DYDROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 62. FRANCE DYDROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 63. GERMANY DYDROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 64. GERMANY DYDROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 65. ISRAEL DYDROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 66. ISRAEL DYDROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 67. ITALY DYDROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 68. ITALY DYDROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 69. NETHERLANDS DYDROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 70. NETHERLANDS DYDROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 71. NIGERIA DYDROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 72. NIGERIA DYDROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 73. NORWAY DYDROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 74. NORWAY DYDROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 75. POLAND DYDROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 76. POLAND DYDROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 77. QATAR DYDROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 78. QATAR DYDROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 79. RUSSIA DYDROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 80. RUSSIA DYDROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 81. SAUDI ARABIA DYDROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 82. SAUDI ARABIA DYDROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 83. SOUTH AFRICA DYDROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 84. SOUTH AFRICA DYDROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 85. SPAIN DYDROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 86. SPAIN DYDROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 87. SWEDEN DYDROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 88. SWEDEN DYDROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 89. SWITZERLAND DYDROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 90. SWITZERLAND DYDROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 91. TURKEY DYDROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 92. TURKEY DYDROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 93. UNITED ARAB EMIRATES DYDROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 94. UNITED ARAB EMIRATES DYDROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 95. UNITED KINGDOM DYDROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 96. UNITED KINGDOM DYDROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 97. DYDROGESTERONE MARKET, FPNV POSITIONING MATRIX, 2023
• TABLE 98. DYDROGESTERONE MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 99. DYDROGESTERONE MARKET LICENSE & PRICING

[199 Pages Report] The Dydrogesterone Market size was estimated at USD 567.86 million in 2023 and expected to reach USD 618.12 million in 2024, at a CAGR 9.45% to reach USD 1,069.00 million by 2030.

Global Dydrogesterone Market

Dydrogesterone is a synthetic hormone similar in chemical structure and pharmacological effect to endogenous progesterone. It is classified as a progestin, which is a type of medication used to replicate the effects of the natural hormone progesterone. Dydrogesterone possesses a strong progestational effect, which makes it highly suitable for conditions related to progesterone deficiency. It is frequently employed in a variety of clinical situations, such as menstrual disorders, infertility owing to luteal insufficiency, and as part of hormone replacement therapy (HRT) for menopausal symptoms. Unlike some other synthetic progestins, dydrogesterone does not inhibit ovulation at therapeutic doses, making it a preferred option in cases where maintenance of ovulatory cycles is desired. The dydrogesterone market is exhibiting growth with an increasing elderly female population and prevalence of reproductive health issues, improved healthcare infrastructure, medical advancements, and supportive government policies for women's health. Despite the growth prospects, challenges such as stringent drug approval regulations, side effects, and competitive alternatives for dydrogesterone hinder the scope of the market. However, developing novel drug delivery mechanisms, introducing generic versions for cost-effectiveness, and investigating combination therapies for broader therapeutic applications present lucrative opportunities for future market growth.

Regional Insights

The dydrogesterone market in the Americas is experiencing a steady growth pattern. The increase in awareness regarding women's health issues and the prevalence of conditions, including endometriosis and irregular menstrual cycles in the female population, bolster the demand for hormone-related treatment options. The United States is a significant contributor to market growth within this region owing to the well-established healthcare infrastructure, presence of major pharmaceutical companies, and supportive regulatory framework. This is coupled with a higher purchasing power and insurance coverage for such medications, aiding in the positive trajectory of the dydrogesterone market. Europe is a major contributor to the dydrogesterone market in the EMEA, with widespread acceptance of hormone replacement therapies and favorable healthcare reimbursement policies. The region's mature healthcare systems contribute to its strong market position. Meanwhile, the Middle East and Africa regions show potential for growth, albeit at a slower rate compared to Europe, due to increasing healthcare investments and the gradual spread of awareness regarding women's reproductive health. The market for dydrogesterone in the Asia-Pacific region is expected to experience the highest growth rate. Factors fueling this expansion include the rising incidence of gynecological disorders, an increase in the female working population, improving healthcare infrastructure, and growing awareness around women's health issues. Particularly, countries including China and India have burgeoning pharmaceutical sectors and represent considerable markets owing to their large populations and increasing medical tourism.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Dydrogesterone Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Dydrogesterone Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Dydrogesterone Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Adalvo Limited, Alembic Pharmaceuticals Limited, Axios Research, Clearsynth, Dr. D Pharma, Gufic Group, H & Care Incorp, Jagsonpal Pharmaceuticals Ltd., Mankind Pharma Limited, Medley Pharmaceuticals Ltd., Merck KGaA, Sandoo Pharmaceuticals and Chemcials Co.,Ltd., Santa Cruz Biotechnology, Inc., Simson Pharma Limited, Solitaire Pharmacia Private Limited, Somacare, Synokem Pharmaceuticals Ltd., Taj Pharmaceuticals Limited, Theramex, TLC Pharmaceutical Standards Ltd., Viatris Inc., VIVAN Life Sciences, and Zuventus Healthcare Limited.

Market Segmentation & Coverage

This research report categorizes the Dydrogesterone Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Type
  • Dydrogesterone D5
  • Dydrogesterone D6
• Application
  • Gynecological Diseases
  • Infertility
• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Dydrogesterone Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Dydrogesterone Market?

3. What are the technology trends and regulatory frameworks in the Dydrogesterone Market?

4. What is the market share of the leading vendors in the Dydrogesterone Market?

5. Which modes and strategic moves are suitable for entering the Dydrogesterone Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Dydrogesterone Market, by Region

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing elderly female population and prevalence of reproductive health issues
    • 5.1.1.2. Supportive government policies for women's health
    • 5.1.1.3. Improved healthcare infrastructure across economies
  • 5.1.2. Restraints
    • 5.1.2.1. High costs associated with dydrogesterone production
  • 5.1.3. Opportunities
    • 5.1.3.1. Rising approval of generic dydrogesterone drugs
    • 5.1.3.2. Growing investment and expansion by market players
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent regulatory approval processes associated with dydrogesterone drugs
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Benefits of dydrogesterone d6 in highly precise analytical and clinical tests
  • 5.2.2. Application: Significant applications of dydrogesterone for symptomatic relief and hormonal regulation in gynecological conditions
• 5.3. Market Trend Analysis
• 5.4. Cumulative Impact of High Inflation
• 5.5. Porter's Five Forces Analysis
  • 5.5.1. Threat of New Entrants
  • 5.5.2. Threat of Substitutes
  • 5.5.3. Bargaining Power of Customers
  • 5.5.4. Bargaining Power of Suppliers
  • 5.5.5. Industry Rivalry
• 5.6. Value Chain & Critical Path Analysis
• 5.7. Regulatory Framework

6. Dydrogesterone Market, by Type

• 6.1. Introduction
• 6.2. Dydrogesterone D5
• 6.3. Dydrogesterone D6

7. Dydrogesterone Market, by Application

• 7.1. Introduction
• 7.2. Gynecological Diseases
• 7.3. Infertility

8. Americas Dydrogesterone Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Dydrogesterone Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Dydrogesterone Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. FPNV Positioning Matrix
• 11.2. Market Share Analysis, By Key Player
• 11.3. Competitive Scenario Analysis, By Key Player
  • 11.3.1. Merger & Acquisition
    • 11.3.1.1. Theramex Announces Agreement to Acquire the European Rights to Duphaston and Femoston From Viatris, Inc.
  • 11.3.2. Award, Recognition, & Expansion
    • 11.3.2.1. Aurisco Gets Auxiton (Dydrogesterone) as First Generic Approval in China
    • 11.3.2.2. US Pharma Giant Applies for Nod to Launch Tweaked Version of Drug for Pelvic Pain in Endometriosis

12. Competitive Portfolio

• 12.1. Key Company Profiles
  • 12.1.1. Abbott Laboratories
  • 12.1.2. Adalvo Limited
  • 12.1.3. Alembic Pharmaceuticals Limited
  • 12.1.4. Axios Research
  • 12.1.5. Clearsynth
  • 12.1.6. Dr. D Pharma
  • 12.1.7. Gufic Group
  • 12.1.8. H & Care Incorp
  • 12.1.9. Jagsonpal Pharmaceuticals Ltd.
  • 12.1.10. Mankind Pharma Limited
  • 12.1.11. Medley Pharmaceuticals Ltd.
  • 12.1.12. Merck KGaA
  • 12.1.13. Sandoo Pharmaceuticals and Chemcials Co.,Ltd.
  • 12.1.14. Santa Cruz Biotechnology, Inc.
  • 12.1.15. Simson Pharma Limited
  • 12.1.16. Solitaire Pharmacia Private Limited
  • 12.1.17. Somacare
  • 12.1.18. Synokem Pharmaceuticals Ltd.
  • 12.1.19. Taj Pharmaceuticals Limited
  • 12.1.20. Theramex
  • 12.1.21. TLC Pharmaceutical Standards Ltd.
  • 12.1.22. Viatris Inc.
  • 12.1.23. VIVAN Life Sciences
  • 12.1.24. Zuventus Healthcare Limited
• 12.2. Key Product Portfolio

13. Appendix

• 13.1. Discussion Guide
• 13.2. License & Pricing